EP2107904A4 - Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use - Google Patents

Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Info

Publication number
EP2107904A4
EP2107904A4 EP07873662A EP07873662A EP2107904A4 EP 2107904 A4 EP2107904 A4 EP 2107904A4 EP 07873662 A EP07873662 A EP 07873662A EP 07873662 A EP07873662 A EP 07873662A EP 2107904 A4 EP2107904 A4 EP 2107904A4
Authority
EP
European Patent Office
Prior art keywords
detoxification
anesthetics
reversal
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07873662A
Other languages
German (de)
French (fr)
Other versions
EP2107904A2 (en
Inventor
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyotropic Therapeutics Inc
Original Assignee
Lyotropic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics Inc filed Critical Lyotropic Therapeutics Inc
Publication of EP2107904A2 publication Critical patent/EP2107904A2/en
Publication of EP2107904A4 publication Critical patent/EP2107904A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07873662A 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use Withdrawn EP2107904A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86895006P 2006-12-07 2006-12-07
PCT/US2007/086642 WO2008127456A2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Publications (2)

Publication Number Publication Date
EP2107904A2 EP2107904A2 (en) 2009-10-14
EP2107904A4 true EP2107904A4 (en) 2010-06-02

Family

ID=39864561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07873662A Withdrawn EP2107904A4 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use

Country Status (5)

Country Link
EP (1) EP2107904A4 (en)
JP (1) JP2010512341A (en)
AU (1) AU2007351338B2 (en)
CA (1) CA2672024C (en)
WO (1) WO2008127456A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871820C (en) * 2012-05-10 2020-11-03 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
JP6255975B2 (en) * 2012-12-27 2018-01-10 Jnc株式会社 Liquid crystal composition, antioxidant and liquid crystal display element

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106589A1 (en) * 2002-06-13 2003-12-24 Lyotropic Therapeutics, Inc. A nanoporous particle with a retained target

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630410A (en) * 1996-01-04 1997-05-20 Us Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
DE69816778T2 (en) * 1997-09-09 2004-04-15 Lyotropic Therapeutics, Inc. COATED PARTICLES, METHOD FOR THEIR PRODUCTION AND USE
AU1493401A (en) * 1999-09-30 2001-04-30 Charlotte-Mecklenburg Hospital Authority Treatment of carbon monoxide poisoning
JP2005530142A (en) * 2002-06-13 2005-10-06 リオトロピック セラピュティックス アイエヌシー． Nanoporous particles holding target substances
US7528172B2 (en) * 2003-01-21 2009-05-05 The Cooper Health System, Inc. Compositions and methods for improving recovery after general anesthesia
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106589A1 (en) * 2002-06-13 2003-12-24 Lyotropic Therapeutics, Inc. A nanoporous particle with a retained target

Also Published As

Publication number Publication date
JP2010512341A (en) 2010-04-22
WO2008127456A3 (en) 2008-12-11
AU2007351338A1 (en) 2008-10-23
AU2007351338B2 (en) 2013-04-04
EP2107904A2 (en) 2009-10-14
CA2672024C (en) 2014-07-08
CA2672024A1 (en) 2008-10-23
WO2008127456A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
HUS1900009I1 (en) Novel compounds and compositions and methods of use
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2023718A4 (en) Creatine-ligand compounds and methods of use thereof
IL193297A0 (en) Imidazole-based compounds, compositions comprising them and methods of their use
HRP20160902T1 (en) Compositions and methods of use of phorbolesters
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
HK1208000A1 (en) Thioninium compounds and their use
ZA200808431B (en) Fungicidal compositions and methods of using the same
EP2079544A4 (en) Arsenic absorbing composition and methods of use
EP2066174A4 (en) Compositions containing alpha-1-antitrypsin and methods for use
GB0611115D0 (en) Compounds and their use
IL192564A0 (en) Composition and method of use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP2107904A4 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
GB0619611D0 (en) Compounds and their use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
ZA201004893B (en) Nuctraceutical composition and methods of use
HUP0600122A2 (en) New compounds and their use
ZA200806668B (en) Antiseptic compositions and methods of using same
IL192614A0 (en) Antiseptic compositions and methods of using same
GB0603378D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090707

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR MK

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20090707

Extension state: HR

Payment date: 20090707

Extension state: AL

Payment date: 20090707

A4 Supplementary search report drawn up and despatched

Effective date: 20100506

17Q First examination report despatched

Effective date: 20110726

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111206